PROCHYMAL Study

*THIS STUDY IS NO LONGER ENROLLING PATIENTS*

People get type 1 diabetes because their immune system, the part of the body which helps fight infections, mistakenly attack cells (beta cells) that produce insulin in your body.  As the immune system destroys these cells, the ability to produce insulin decreases and diabetes develops.

The goal of this study is to learn if PROCHYMAL™ is safe and effective for people with newly diagnosed type 1 diabetes by delaying or stopping the further destruction of beta cells.

If you are interested in more information on A Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PROCHYMAL™ (ex vivo cultured adult human mesenchymal stem cells) for the treatment of recently diagnosed type 1 diabetes mellitus (T1DM) trial, please contact:

Theresa Albright-Fischer, RN, BSN
Phone:  612-626-2182
Toll free:  800-688-5252 Ext. 62182
Email:  albr0088@umn.edu

You can download and print forms for the study by clicking on each document name.

Adult Consent & Parental Consent(must be reviewed with staff at the University of Minnesota and signed for all being tested)

HIPPA (for confidentiality of medical information)

Assent ages 12-14 (must be reviewed with staff at the University of Minnesota and signed for all being tested)

Assent ages 15-17 must be reviewed with staff at the University of Minnesota and signed for all being tested)